Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2025-10-15 00:00:00 ET · period of report 2025-10-15 · accession 0001193125-25-240430 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-10-15 | 2025-10-15 | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $1.64 | +51.2K | 147.4K | +53% | +$84.2K |
| DMT | 2025-10-15 | 2025-10-15 | KYMR | Gollob Jared | Chief Medical Off | S - Sale+OE | $61.42 | -59.6K | 131.3K | -31% | -$3.66M |
| DMT | 2025-10-15 | 2025-10-15 | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $0.00 | -51.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-15 | M | A | 22,210 | $2.08 | 169,568 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-15 | S | D | 29,264 | $60.37 | 140,304 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-10-15 | S | D | 6,453 | $63.09 | 109,992 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.02 to $63.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-10-15 | S | D | 14,896 | $62.72 | 116,445 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.01 to $63.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2025-10-15 | M | A | 28,999 | $1.31 | 147,358 | D | — | — | |
| 6 | Common | Common Stock | 2025-10-15 | S | D | 8,963 | $61.49 | 131,341 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.01 to $62.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Stock Option (Right to Buy) | 2025-10-15 | M | D | 22,210 | $0.00 | 0 | D | $2.08 · — to 2029-05-22 | 22,210 Common Stock | (F6) The shares underlying this stock option are fully vested and exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2025-10-15 | M | D | 28,999 | $0.00 | 0 | D | $1.31 · — to 2028-10-31 | 28,999 Common Stock | (F6) The shares underlying this stock option are fully vested and exercisable. |